Theravance Biopharma, Inc. (TBPH)
17.04
0.00 (0.00%)
USD |
NASDAQ |
Aug 28, 16:00
17.04
0.00 (0.00%)
After-Hours: 20:00
Theravance Biopharma Cash from Operations (Quarterly) : -6.965M for June 30, 2026
Cash from Operations (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -6.965M |
| March 31, 2026 | 73.28M |
| December 31, 2025 | -6.064M |
| September 30, 2025 | -6.508M |
| June 30, 2025 | 208.07M |
| March 31, 2025 | 43.04M |
| December 31, 2024 | -0.902M |
| September 30, 2024 | -5.196M |
| June 30, 2024 | -4.415M |
| March 31, 2024 | -1.022M |
| December 31, 2023 | -0.854M |
| September 30, 2023 | -2.486M |
| June 30, 2023 | -12.44M |
| March 31, 2023 | -11.22M |
| December 31, 2022 | -124.06M |
| September 30, 2022 | -22.14M |
| June 30, 2022 | -14.73M |
| March 31, 2022 | -26.07M |
| December 31, 2021 | -42.43M |
| September 30, 2021 | -45.45M |
| June 30, 2021 | -50.11M |
| March 31, 2021 | -69.86M |
| December 31, 2020 | -64.92M |
| September 30, 2020 | -77.03M |
| June 30, 2020 | -53.35M |
| Date | Value |
|---|---|
| March 31, 2020 | -55.10M |
| December 31, 2019 | -64.35M |
| September 30, 2019 | -44.62M |
| June 30, 2019 | -48.03M |
| March 31, 2019 | -81.19M |
| December 31, 2018 | -52.18M |
| September 30, 2018 | -48.98M |
| June 30, 2018 | -61.54M |
| March 31, 2018 | 49.82M |
| December 31, 2017 | -44.20M |
| September 30, 2017 | -62.30M |
| June 30, 2017 | -44.52M |
| March 31, 2017 | -50.03M |
| December 31, 2016 | -28.11M |
| September 30, 2016 | -12.43M |
| June 30, 2016 | -32.14M |
| March 31, 2016 | -26.31M |
| December 31, 2015 | -33.75M |
| September 30, 2015 | -31.98M |
| June 30, 2015 | -46.61M |
| March 31, 2015 | -56.51M |
| December 31, 2014 | -42.54M |
| September 30, 2014 | -36.38M |
| June 30, 2014 | -51.44M |
| March 31, 2014 | -44.80M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Zymeworks, Inc. | -31.59M |
| Viatris, Inc. | 381.80M |
| Ocular Therapeutix, Inc. | -67.27M |
| ANI Pharmaceuticals, Inc. | 56.67M |
| Corcept Therapeutics, Inc. | 33.54M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -60.40M |
| Cash from Financing (Quarterly) | -0.967M |
| Free Cash Flow | 53.73M |
| Free Cash Flow Per Share (Quarterly) | -0.1348 |
| Free Cash Flow to Equity (Quarterly) | -5.03M |
| Free Cash Flow to Firm (Quarterly) | -6.965M |
| Free Cash Flow Yield | 6.07% |